Search

Your search keyword '"Miller, Timothy M."' showing total 46 results

Search Constraints

Start Over You searched for: Author "Miller, Timothy M." Remove constraint Author: "Miller, Timothy M." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
46 results on '"Miller, Timothy M."'

Search Results

1. The expanding application of antisense oligonucleotides to neurodegenerative diseases

2. Characterization of Low-noise Backshort-Under-Grid Kilopixel Transition Edge Sensor Arrays for PIPER

3. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology

4. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial

8. TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy

9. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients

14. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients

19. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

20. TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma

21. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

22. Protein kinetics of superoxide dismutase‐1 in familial and sporadic amyotrophic lateral sclerosis

23. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

24. Courage-als: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

26. A dual MTOR/NAD+ acting gerotherapy

29. MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial

30. Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers

31. DNAJB6 Isoform Specific Knockdown: Therapeutic Potential for LGMDD1

32. Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model.

33. MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.

35. DNAJB6 Isoform Specific Knockdown: Therapeutic Potential for LGMDD1

36. Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational Studies

37. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A

39. Characterizations of Optimized Microshutter Arrays For Space Borne Observatory Applications

42. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients

43. Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.

44. Access for ALL in ALS: A large‐scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis.

45. Lipid-siRNA conjugate accesses perivascular transport and achieves durable knockdown throughout the central nervous system.

46. A DUAL MTOR/NAD+ ACTING GEROTHERAPY.

Catalog

Books, media, physical & digital resources